



CODEN [USA]: IAJPBB

ISSN : 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

<http://doi.org/10.5281/zenodo.4289535>Available online at: <http://www.iajps.com>

Research Article

**AN OVERVIEW OF MECHANISMS OF ANTIBIOTIC  
RESISTANCE****<sup>1</sup>Shaymah Ahmed Sharahili, <sup>2</sup>Huda Ahmed Sharahili, <sup>3</sup>Abeer Ahmed Sharahili, <sup>4</sup>Halah Farhan Alhayel, <sup>5</sup>Anwar Mohammed Alanazi**<sup>1</sup>Pinklip17@hotmail.com<sup>2</sup>H.Sharahili@outlook.com<sup>3</sup>Dr.abeer14@hotmail.com<sup>4</sup>Elham13@hotmail.com<sup>5</sup>Nawar44@hotmail.com**Article Received: September 2020 Accepted: October 2020 Published: November 2020****Abstract:**

*The aim of this overview was to highlight the most important aspects about mechanisms of antibiotics resistance. also we attempted to discuss the benefits of antibiotics and its resistance crisis. We conducted a comprehensive review of literature concerning antibiotics resistance through electronic search in several databases; MIDLINE, EMBASE, GOOGLE Scholar, up to July 2020. We identified most important studies related to our concerned topic for reviewing the mechanism of antibiotic resistance. The value and worth of antibiotics cannot be overstated; we are absolutely relying on them for the treatment of infectious conditions, as well as they need to never ever be thought-about basic products. Along with their usage in the treatment of transmittable conditions, antibiotics are important to the success of cutting-edge surgical procedures, consisting of an organ and also prosthetic transplants. No matter all excellent intents to manage antibiotic usage (nonetheless limited activity), there is little doubt that the situation relative to antibiotic resistance. Resistance mechanisms are pandemic and also produce significant clinical and financial worry on medical care systems worldwide. There are no standard solutions to the issue. Conclusive actions that require substantial dedication, as well as enforcement, are never ever prominent, even if lives can be preserved. It is vitally important that we have a clear photo of the number of these resistance systems private microorganisms might have in their arsenals.*

**Corresponding author:****Shaymah Ahmed Sharahili,**[Pinklip17@hotmail.com](mailto:Pinklip17@hotmail.com)

QR code



Please cite this article in press Shaymah Ahmed Sharahili et al, *An Overview Of Mechanisms Of Antibiotic Resistance.*, *Indo Am. J. P. Sci.*, 2020; 07(11).

## INTRODUCTION:

Antibiotics in the biosphere are produced by microorganisms as secondary metabolites at a concentration much lower than the therapeutic dosage. Waksman was convinced that antibiotics play "no genuine part in influencing or customizing living processes that take place in nature" <sup>(1)</sup> though there is evidence to the contrary <sup>(2)</sup>. Resistance to antimicrobial agents has become a major source of morbidity and mortality worldwide. Present research study studies <sup>(3,4,5,6)</sup> reveal that antibiotics do have some certain results on the all-natural scene of the bacteria while they presume a totally different function as antibacterial agents in the dose made use of in rehabilitation <sup>(3,4,5,6)</sup>.

Antibiotic resistance is 'bacteria changing in manner in which eliminate the efficiency or decrease of antibiotics efficiency' <sup>(9)</sup>. These changes are because of bacterial improvement, as well as endanger the solitary greatest therapeutic advance in the background of medication. The quick development of resistant bacteria is happening worldwide, endangering the efficiency of antibiotics, which have actually changed medicine as well as saved wide populations of many infectious diseases <sup>(5,6,7,8)</sup>. Several years after the really first patients were treated with antibiotics, bacterial infections have once more wind up being a danger <sup>(8)</sup>. The antibiotic resistance situation has in fact been credited to the overuse and also misuse of these antibiotics, in addition to an absence of new medicine development by the pharmaceutical market due to reduced monetary incentives and also hard regulative requirements <sup>(9,10,11)</sup>.

The aim of this overview was to highlight the most important aspects about mechanisms of antibiotics resistance. also we attempted to discuss the benefits of antibiotics and its resistance crisis.

## METHODOLOGY:

We conducted a comprehensive review of literature concerning antibiotics resistance through electronic search in several databases; MIDLINE, EMBASE, GOOGLE Scholar, up to July 2020. We identified most important studies related to our concerned topic

forreviewing the mechanism of antibiotic resistance and approaches to control this crisis, we limited our search to English language and human subject.

## DISSCUSION:

### Advantage of antibiotics:

Antibiotics have not just preserved patient's lives; they have played a crucial function in attaining major advancements in the medical field <sup>(6)</sup>. They have actually efficiently treated infections that can occur in people that are receiving chemotherapy treatments; who have morbidities diseases such as diabetes mellitus, end-stage kidney disease, or rheumatoid arthritis; or who have had complex surgical treatments such as organ transplants, joint replacements, or heart surgical therapy <sup>(6,7,9)</sup>.

Prescribed antibiotics have beneficial roles to extend anticipated life periods by altering the end result of bacterial infections <sup>(20,21)</sup>. In developing nations where hygiene is still poor, antibiotics lower the morbidity and mortality triggered by food-borne and also various other poverty-related infections <sup>(21)</sup>.


Considering that antibiotics developed in 1937 of the initial dependable antimicrobials, particularly, the sulfonamides, the growth of particular systems of resistance has actually plagued their restorative use. Sulfonamide resistance was first reported in the late 1930s, and the identical systems run some 70 years in the future <sup>(13)</sup>. A collection of the often-utilized antibiotics, their settings of action, and resistance mechanisms is displayed in (Table 1) <sup>(14)</sup>. Penicillin was discovered by Alexander Fleming in 1928, and in 1940, many years prior to the introductory of penicillin as a healing, a microbial penicillinase was established by two members of the penicillin discovery team <sup>(13)</sup>. When the antibiotic was made use of extensively, resistant strains efficient in inactivating the drug crisis being widespread, and also research studies were accomplished to customize penicillin chemically to avoid cleavage by penicillinases ( $\beta$ -lactamases). Extremely, the recognition of a bacterial penicillinase before making use of the antibiotic can now be valued in the light of current findings that a lot of antibiotic r genes are components of all-natural microbial populaces <sup>(15)</sup>.

**Table1:** Modes of action and resistance mechanisms of commonly used antibiotics<sup>(14)</sup>

Antibiotic class	Example(s)	Target	Mode of resistance
$\beta$ -Lactams	Penicillins (ampicillin), cephalosporins (cephamycin), penems (meropenem), monobactams (aztreonam)	Peptidoglycan biosynthesis	Hydrolysis, efflux, altered target
Aminoglycosides	Gentamicin, streptomycin, spectinomycin	Translation	Phosphorylation, acetylation, nucleotidylation, efflux, altered target
Glycopeptides	Vancomycin, teicoplanin	Peptidoglycan biosynthesis	Reprogramming peptidoglycan biosynthesis
Tetracyclines	Minocycline, tigecycline	Translation	Monooxygenation, efflux, altered target
Macrolides	Erythromycin, azithromycin	Translation	Hydrolysis, glycosylation, phosphorylation, efflux, altered target
Lincosamides	Clindamycin	Translation	Nucleotidylation, efflux, altered target
Streptogramins	Synercid	Translation	C-O lyase (type B streptogramins), acetylation (type A streptogramins), efflux, altered target
Oxazolidinones	Linezolid	Translation	Efflux, altered target
Phenicols	Chloramphenicol	Translation	Acetylation, efflux, altered target
Quinolones	Ciprofloxacin	DNA replication	Acetylation, efflux, altered target
Pyrimidines	Trimethoprim	C <sub>1</sub> metabolism	Efflux, altered target
Sulfonamides	Sulfamethoxazole	C <sub>1</sub> metabolism	Efflux, altered target
Rifamycins	Rifampin	Transcription	ADP-ribosylation, efflux, altered target
Lipopeptides	Daptomycin	Cell membrane	Altered target
Cationic peptides	Colistin	Cell membrane	Altered target, efflux

**Mechanism of antibiotics resistance:**

The purpose of resistance monitoring is to stop medical failures brought on by high-level bacterial resistance to the antibiotics. Resistance is typically a continuous trait, and there can be at different levels of intermediate to moderate to severe resistance. Often described as "tolerance," intermediate resistance gives the capability to make it through focus of drug listed below those considered treatment (**Figure 1**)<sup>(12)</sup>.



**Figure 1:** Hypothetical path to drug resistance. Solid curves show drug concentration in a treated patient for two drugs with different half-lives; concentrations wane when treatment ceases. In this schematic, wild type parasites can survive very low concentrations, with mutations A, B, and C conferring the ability to survive (“tolerate”) successively higher drug concentrations<sup>(12)</sup>.

Molecular mechanism systems of resistance to prescription antibiotics have actually been studied thoroughly (**Table 1**) and have in fact consisted of assessments of the genetics and also biochemistry and biology of different components of bacterial cell function<sup>(16,17,18)</sup>. The research study of antibiotic activity and also resistance has actually contributed considerably to our understanding of cell framework as well as feature. Resistance treatments are frequently dispersed in the bacterial world and also have in fact been well explained for a variety of commensals<sup>(19)</sup> and microorganisms; most can be shared by several one-of-a-kind genetics transfer systems. A few of the resistance types that reveal the troubles in maintaining efficient antibiotic activity in the face of the biochemical and also hereditary versatility of germs deserve unique recommendation.

#### Intrinsic resistance:

Intrinsic resistance describes the presence of genes in bacterial genomes that might create a resistance phenotype, i.e., proto- or quasi-resistance. Provided that the beginning of this millennium, the routine of genome large mutagenesis methods and also quick microbial genome sequencing has in fact revealed lots of potential/intrinsic genetics functions in bacteria that could cause resistance phenotypes in scientific terms. A typical hereditary course to boosted antibiotic resistance is gene amplification, considerably for resistance to the sulfonamides<sup>(22)</sup> as well as trimethoprim<sup>(23)</sup>.

#### Antibiotic resistance in Gram-positive Bacteria:

A crisis however still under control Among Gram-positive pathogens, *Staphylococcus aureus* and *Enterococcus* spp. are the kinds which currently posture the significant barriers in relation to antibiotic resistance. Methicillin-resistant *S. aureus* (MRSA), emerged for 5 years, has really been the really initial considerable gamer in the antibiotic resistance crisis, showing worldwide diffusion and a considerable effect on medical results versus methicillin-susceptible *S. aureus*<sup>(24,25,26)</sup>. The MRSA phenotype is a result of the expression of customized penicillin-binding proteins (PBPs), inscribed by the flat obtained genetics, that takes control of the features of the resident staphylococcal PBPs and also is not protected against by conventional  $\beta$ -lactams. MRSA rates are instead high in a number of countries in Europe, the Americas, and the Asia Pacific location, where MRSA remains an important factor for human infections<sup>(27,28,29)</sup>. In some countries, however, aggressive infection control projects have really revealed reliability at avoiding MRSA dissemination (e.g. in the Netherlands)<sup>(27)</sup> or at reducing a presently established MRSA endemicity (e.g. in the United Kingdom)<sup>(27,30)</sup>, showing that infection control can be extremely trustworthy at limiting MRSA dissemination. On the other hand, there are still a variety of medicines which preserve activity versus MRSA, containing the glycopeptides (e.g. vancomycin as well as teicoplanin), linezolid, tigecycline, daptomycin in addition to some new  $\beta$ -lactams, such as ceftaroline and ceftobiprole, that are

energetic versus the customized PBPs in charge of the methicillin-resistant phenotype<sup>(31)</sup>. Resistance to any of these medicines has actually been reported, the resistance rates remain basic exceptionally low<sup>(32,33,34)</sup>, while XDR or TDR MRSA tension has really not been consistently reported.

#### Antibiotic resistance in Gram-negative pathogens:

A crisis going out of control with Gram-negative pathogens the antibiotic crisis is presently a lot more major than with the Gram-positives. The event of XDR as well as also TDR phenotypes has actually been frequently reported amongst Gram-negative bacteria connected with HAIs, such as *Pseudomonas aeruginosa*, *Acinetobacter* spp. and Enterobacteriaceae (primarily *Klebsiella pneumoniae* (35). On the other hand, MDR Gram-negatives are considerably typical likewise in the neighborhood, containing *Escherichia coli* producing extended-spectrum beta-lactamases (ESBLs) (35), as well as *Neisseria gonorrhoeae* resistant to fluoroquinolones, penicillin, azithromycin as well as tetracycline or expanded-spectrum cephalosporin. *P. aeruginosa* has in fact likely been the extremely initial pathogen to reveal MDR and also XDR phenotypes, with the growth of stress-resistant to all classes of anti-pseudomonal reps other than polymyxins (likewise called Colistin-Only Susceptible-COS- stress). MDR and XDR pressures of *P. aeruginosa* are discovered as agents of high-risk clones belonging in global clonal family trees, such as ST111, st175 and st235<sup>(35)</sup>.

#### **CONCLUSION:**

The value and worth of antibiotics cannot be overstated; we are absolutely relying on them for the treatment of infectious conditions, as well as they need to never ever be thought-about basic products. Along with their usage in the treatment of transmittable conditions, antibiotics are important to the success of cutting-edge surgical procedures, consisting of an organ and also prosthetic transplants. No matter all excellent intents to manage antibiotic usage (nonetheless limited activity), there is little doubt that the situation relative to antibiotic resistance. Resistance mechanisms are pandemic and also produce significant clinical and financial worry on medical care systems worldwide. There are no standard solutions to the issue. Conclusive actions that require substantial dedication, as well as enforcement, are never ever prominent, even if lives can be preserved. It is vitally important that we have a clear photo of the number of these resistance systems private microorganisms might have in their arsenals. A crucial and also outstanding instance of this is MRSA. The increase in costs for MRSA

infections was stated previously. These enhanced expenses are affected by the excess length of healthcare facilities remain, increases in a variety of examinations required, and raised medical and also rehab solutions provided. We also need to think of the effect on morbidity and death caused by MRSA, including significant rises in disease problems. The introductory of these new compounds in scientific techniques is anticipated no faster than 3-5 years. Awaiting these new medications, the only selections that are currently used to handle the antibiotic resistance situation are stood for by improving routines concentrated on lowering the dissemination of microorganisms, and also optimization of the readily available antimicrobial treatment programs on the purpose of the most reliable dosing routines.

#### **REFERENCES:**

1. Waksman S. A. (1961). The role of antibiotics in nature. *Perspect. Biol. Med.* 4 271–286
2. Gullberg E., Cao S., Berg O G., Illback C., Sandegren L., Hughes D., et al. (2011). Selection of resistant bacteria at very low antibiotic concentrations. *PLoS Pathog.* 7:e1002158. doi:10.1371/journal.ppat.1002158
3. Davies J. (2009). Darwin and microbiomes. *EMBO Rep.* 10 805
4. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. *AIMS Microbiol.* 2018;4(3):482-501. Published 2018 Jun 26. doi:10.3934/microbiol.2018.3.482
5. Golkar Z, Bagazra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. *J Infect Dev Ctries.* 2014;8(2):129–136. 13.
6. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can overcome microbial resistance. *Virulence.* 2013;4(2):185–191.
7. Wright GD. Something new: revisiting natural products in antibiotic drug discovery. *Can J Microbiol.* 2014;60(3):147–154.
8. Sengupta S, Chattopadhyay MK, Grossart HP. The multifaceted roles of antibiotics and antibiotic resistance in nature. *Front Microbiol.* 2013;4:47.
9. Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. *Clin Infect Dis.* 2014;59 (suppl 2):S71–S75.
10. Viswanathan VK. Off-label abuse of antibiotics by bacteria. *Gut Microbes.* 2014;5(1):3–4.
11. Read AF, Day T, Huijben S. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. *Proceedings of the National Academy of Sciences of the United*



- States of America*. 2011;108(Suppl 2):10871-10877. doi:10.1073/pnas.1100299108.
12. Abraham, E. P., and E. Chain. 1940. An enzyme from bacteria able to destroy penicillin. *Rev. Infect. Dis.* 10:677-678.
  13. Wright, G. D., and M. Morar. The genomic enzymology of antibiotic resistance. *Annu. Rev. Genet.*, in press.
  14. D'Costa, V. M., K. M. McGrann, D. W. Hughes, and G. D. Wright. 2006. Sampling the antibiotic resistome. *Science* 311:374-377.
  15. Allen, H. K., J. Donato, H. H. Wang, K. A. Cloud-Hansen, J. E. Davies, and J. Handelsman. 2010. Call of the wild: antibiotic resistance genes in natural environments. *Nat. Rev. Microbiol.* 8:251-259.
  16. Gale, E. F., E. Cundliffe, P. E. Reynolds, M. H. Richmond, and M. J. Waring (ed.). 1981. *The molecular basis of antibiotic action*, 2nd ed. John Wiley, Chichester, United Kingdom.
  17. Walsh, C. 2003. *Antibiotics: actions, origins, resistance*. ASM Press, Washington, DC.
  18. Marshall, B. M., D. J. Ochieng, and S. B. Levy. 2009. Commensals: unappreciated reservoir of antibiotic resistance. *Microbe* 4:231-238.
  19. Piddock LJ. The crisis of no new antibiotics—what is the way forward? *Lancet Infect Dis.* 2012;12(3):249–253.
  20. Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. *ClinOpinPharmacol.* 2014;18:56–60.
  21. Kashmiri, S. V. S., and R. D. Hotchkiss. 1975. Evidence of tandem duplication of genes in a merodiploid region of pneumococcal mutants resistant to sulfonamide. *Genetics* 81:21.
  22. Brochet, M., E. Couvé, M. Zouine, C. Poyart, and P. Glaser. 2008. A naturally occurring gene amplification leading to sulfonamide and trimethoprim resistance in *Streptococcus agalactiae*. *J. Bacteriol.* 190:672-680.
  23. WHO (World Health Organization): Antimicrobial Resistance: Global Report on surveillance. 2014 [http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf).
  24. Boucher H, Miller LG, Razonable RR: Serious infections caused by methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 2010, 51(Suppl. 2):S183-S197.
  25. Hanberger H, Walther S, Leone M, Barie PS, Rello J, Lipman J, Marshall JC, Anzueto A, Sakr Y, Pickkers P et al.: Increased mortality associated with methicillin-resistant *Staphylococcus aureus* (MRSA) infection in the intensive care unit: results from the EPIC II study. *Int J Antimicrob Agents* 2011, 38:331-335.
  26. ECDC: European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network. 2013.
  27. David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG, Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ et al.: *Staphylococcus aureus* bacteremia at five U.S. academic medical centers, 2008–2011: significant geographic variation in community-onset infections. *Clin Infect Dis* 2014 <http://dx.doi.org/10.1093/cid/ciu410>.
  28. Chen C-J, Huang Y-C: New epidemiology of *Staphylococcus aureus* infection in Asia. *ClinMicrobiol Infect* 2014;1270 <http://dx.doi.org/10.1111/1469-0691.5>.
  29. Johnson AP, Davies J, Guy R, Abernethy J, Sheridan E, Pearson A, Duckworth G: Mandatory surveillance of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteraemia in England: the first 10 years. *J AntimicrobChemother* 2012, 67:802-809.
  30. Kurosu M, Siricilla S, Mitachi K: Advances in MRSA drug discovery: where are we and where do we need to be? *Expert Opin Drug Discov* 2013, 8:1095-1116. 14. Sader HS,
  31. Farrell DJ, Flamm RK, Jones RN: Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005–2012). *Int J Antimicrob Agents* 2014, 43:465-469.
  32. Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD: Analysis of *Staphylococcus aureus* clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. *J AntimicrobChemother* 2014 <http://dx.doi.org/10.1093/jac/dku114>.
  33. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B et al.: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *ClinMicrobiol Infect* 2012, 18:268-281.
  34. Livermore DM: Current epidemiology and growing resistance of Gram-negative pathogens. *Korean J Intern Med* 2012, 27:128-142.
  35. Pendleton JN, Gorman SP, Gilmore BF: Clinical relevance of the ESKAPE pathogens. *Expert Rev Anti Infect Ther* 2013, 11:297-308.